secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aprea Therapeutics, Inc. (APRE)
CIK:        0001781983
Form:       8-K
Filed at:   2026-01-29T23:59:59+00:00
Accession:  0001104659-26-007988
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 1.01, 3.02, 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aprea reports first partial response for APR-1051; raises $5.6M in private placement
--------------------------------------------------------------------------------

- First unconfirmed partial response (uPR) in PPP2R1A-mutated endometrial cancer at 150 mg: 50% target lesion reduction, CA-125 from 732 to 70 U/mL.
- Stable disease at 70 mg (HNSCC, 5% reduction) and 100 mg (colon cancer, 15% reduction; >210 days on therapy).
- Private placement ~$5.6M gross: 6.3M shares/pre-funded warrants + 6.3M warrants at $0.765; priced $0.89/unit. Closes Jan 30, 2026.
- Dose escalation continues; 220 mg cohort enrolling; company plans to increase HPV-positive enrollment.
- Potential dose-response trend observed across 70 mg, 100 mg, and 150 mg cohorts.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1781983/000110465926007988/0001104659-26-007988-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1781983/000110465926007988/tm264417d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-007988

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer